Loading company…
Neurosterix discovers and develops allosteric modulators for neurological disorders.
Neurosterix is a pharmaceutical research company focused on developing treatments for neurological disorders. It discovers and develops allosteric modulators, including a lead M4 positive allosteric modulator programme for schizophrenia. The company is based in Geneva, Switzerland. In April 2024, it raised USD 63 million in Series A funding led by Perceptive Xontogeny Venture Fund, with participation from Perceptive Advisors and Acorn Bioventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in